Resumen

COMBARIZA-VALLEJO, Juan Felipe. Survival cohort of patients under 60 years with acute myeloid leukemia according to cytogenetics and consolidation treatment. Iatreia [online]. 2015, vol.28, n.4, pp.378-387. ISSN 0121-0793.  https://doi.org/10.17533/udea.iatreia.v28n4a03.

Introduction: Survival of patients with acute myeloid leukemia (AML) differs according to karyotype and the treatment they receive. Methods: In this retrospective cohort we evaluated survival, its prognostic factors and its association with the initial karyotype in 66 patients younger than 60 years with AML, who received chemotherapy or allogeneic bone marrow transplantation. Results: Overall survival at 2 years was 90 % in the low risk group, 61 % in the intermediate risk group and 30 % in the high risk group (p = 0.016). The following factors affected overall survival: not having reached complete remission (HR: 16.36; IC 95 %: 6.17-43.33), and not having received haematopoietic stem cell transplantation (HR: 4.76; IC 95 %: 1.36-16.69). As risk factor for relapse we found: High risk karyotype (HR: 9.18; IC 95 %: 1.22- 68.56) and not having performed haematopoietic stem cell transplantation (HR: 3.06; IC 95 %: 1.14-8.18). Conclusion: This study suggests that in Colombia the global survival of young patients with AML with intermediate or high cytogenetic risk at diagnosis may improve when they receive hematopoietic stem cell transplantation as part of the treatment.

Palabras clave : Acute Myeloid Leukaemia; Colombia; Hematopoietic Stem Cell Transplantation; Karyotype.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )